Question-and-Answer Session
(Operator Instructions) Your first question comes from the line of Adam Feinstein. Please, proceed sir.
Adam Feinstein - Barclays Capital
Okay, thank you. Good morning, everyone.
Dave King
Good morning.
Adam Feinstein - Barclays Capital
Just everything looks very good here. Just a few questions, I guess. Maybe just first on the guidance, just curious why you are not incorporating, Monogram? I know you broke it out for us, so we can know the impact, but just wanted to see in terms of why you weren’t incorporating that and then I’ve got a few follow-up questions.
Dave King
Adam, its Dave. Good morning. We haven’t incorporated it because it hasn’t closed yet and so, I think it would be somewhat confusing to incorporate it prior to the time that the transaction closes. Once it closes, then we’ll in a position to have an exact idea of where we think it’s going to come out.
Adam Feinstein - Barclays Capital
You still anticipate closing in Q3?
Dave King
We have received notice from the FDC as we disclosed that the transaction has cleared HSR. The tender offer is underway and it’s proceeding inline with our expectations. So, barring some unforeseen circumstance, yes we would expect to close in Q3.
Adam Feinstein - Barclays Capital
Okay, great. Okay and then just as we look at the mix of cash, and we’ve seen it turn for several quarters, but I just one I wanted to got some more colors here, but in terms of the esoteric testing significantly outpacing the core volumes and just clearly core volumes have been impacted by the economy somewhat, but really have seen no impact; it looks like on the esoteric side.
So, just curious to get your thoughts in terms of that trend, do you think we’ll continue to see such a big spread between the different segments through the rest half of the year?
Brad Hayes
Hey Adam, it’s Brad. Traditionally, that group has grown faster than the core. I would add and it’s consistent with past quarters, vitamin D continues to be a big grower in that category and even HPV as well continues to grow. So we certainly expect that over time that category grows faster than the core.
Adam Feinstein - Barclays Capital
Okay, great. Okay and then just my final question here and Bill you had mentioned the CPI impact in terms of Medicare, but there’s been a lot of questions in the last couple weeks about whether there is an impact in terms of the escalators in Managed Care contracts, in terms of whether they are linked to CPI or other inflationary measures.
- To read the full transcript on Seeking Alpha, click here »
